Phase 2 Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have given their written consent to take part in the study
- People aged between 18 and 55 years old
- People who have been diagnosed with clinically isolated syndrome (CIS) or multiple sclerosis (MS) at their first presentation of symptoms
- People whose MRI brain scan shows two or more areas of damage that suggest the protective covering of nerves has been affected
- People who are willing and able to attend clinic visits and follow the steps outlined in the study plan
Who may not be able to join:
- People who have had an allergic reaction to Tyruko® or any of its ingredients, including histidine, histidine monohydrochloride, sodium chloride, polysorbate 80 (E433), or water for injections
- People whose MRI shows multiple long-standing areas of nerve damage with no signs of recent activity
- People who have a weakened immune system, including those currently taking or previously treated with medications that suppress the immune system
- People who are already taking other disease-modifying treatments for their condition
- People who currently have an active cancer, except for a specific type of non-invasive skin cancer (basal cell carcinoma)
- People who have certain implanted medical devices, such as a pacemaker, a brain aneurysm clip, or a heart valve that is not safe for MRI scans
- People with serious ongoing health conditions such as heart failure, kidney failure, uncontrolled diabetes, or uncontrolled high cholesterol
- People who have a history of stroke, blood clots, or a heart attack
- People who have any other infection that the trial doctor considers to be medically significant
- People who experience severe anxiety in enclosed spaces (claustrophobia)
- People who are pregnant or currently breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Klaus Schmierer, Queen Mary University of London
Phone: +44 20 7882 6246
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To establish whether there is efficacy superiority of Natalizumab (Tyruko®) over placebo at 12 weeks in facilitating remyelination of previously demyelinated CNS lesions, as measured by MRI lesion magnetization transfer ratio (MTR).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.